Ying Lan Wu

6524542, Feb 25, 2003

Apr 12, 2001

09/833904

Steven C. Amendola - Ocean NJ
Michael T. Kelly - Plainsboro NJ
Ying Wu - Red Bank NJ

Millennium Cell, Inc. - Eatontown NJ

C01B 610

423286, 423287, 423288

Processes for synthesizing borohydride compounds with reduced energy requirements are disclosed.

6586563, Jul 1, 2003

Dec 18, 2001

10/022077

Jeffrey V. Ortega - Dover Township, Ocean County NJ
Ying Wu - Red Bank NJ
Steven C. Amendola - Ocean Township, Monmouth County NJ
Michael T. Kelly - Plainsboro Township, Middlesex County NJ

Millennium Cell, Inc. - Eatontown NJ

C08G 7908

528394, 528271, 528396

Processes for synthesizing borohydride compounds with reduced energy requirements and high efficiency are disclosed. The processes include the reaction of a base with a borane complex or diborane to produce a borohydride compound of formula YBH , where Y is a monovalent cationic moiety.

20030092877, May 15, 2003

Dec 27, 2002

10/331674

Steven Amendola - Ocean NJ, US
Michael Kelly - Plainsboro NJ, US
Jeffrey Ortega - Dover NJ, US
Ying Wu - Red Bank NJ, US

C08G079/08

528/394000, 528/230000, 528/241000, 528/482000, 528/488000, 528/492000

The present invention relates to processes for producing borohydride compounds. In particular, the present invention provides efficient processes and compositions for the large-scale production of borohydride compounds of the formula YBHby the reaction of a boron-containing compound represented by the formula BXwith hydrogen or an aldehyde to obtain diborane and HX, and reacting the diborane with a Y-containing base selected from those represented by the formula YO, YOH and YCOto obtain YBHand YBO. Y is selected from the group consisting of the alkali metals, pseudo-alkali metals, alkaline earth metals, an ammonium ion, and quaternary amines of the formula NR, wherein each R is independently selected from hydrogen and a straight- or branched-chain Calkyl group, and X is selected from the group consisting of halide ions, —OH, —R′ and —OR′ groups, chalcogens, and chalcogenides, wherein R′ is a straight- or branched-chain Calkyl group.

20060292067, Dec 28, 2006

Jun 28, 2005

11/167607

Qinglin Zhang - Manalpan NJ, US
Ying Wu - Red Bank NJ, US
Gregory Smith - Marlboro NJ, US
Michael Binder - Brooklyn NY, US

C01B 3/02

423648100

Supported catalyst methods are provided to promote hydrogen generation from the hydrolysis of boron hydrides. The methods use a supported catalyst which is a supported metallic mixture comprising a first transition metal selected from the group consisting of cobalt, ruthenium, zinc, molybdenum, manganese, titanium, tin, cadmium, and iridium, in an amount of from about 0.1 to about 20% by weight, and a second metal selected from the group consisting of cobalt, ruthenium, zinc, molybdenum, manganese, titanium, tin, cadmium, boron, and iridium, in an amount of from about 0.05 to about 25% by weight of the supported catalyst.

20060293173, Dec 28, 2006

Jun 28, 2005

11/167608

Qinglin Zhang - Manalpan NJ, US
Ying Wu - Red Bank NJ, US
Gregory Smith - Marlboro NJ, US
Michael Binder - Brooklyn NY, US

B01J 23/32
B01J 21/18
B01J 23/60

502182000, 502324000, 502329000, 502183000, 502185000

Supported catalysts are provided to promote hydrogen generation from the hydrolysis of boron hydrides. The supported catalyst is a supported metallic mixture comprising a first transition metal selected from the group consisting of cobalt, ruthenium, zinc, molybdenum, manganese, titanium, tin, cadmium, and iridium, in an amount of from about 0.1 to about 20% by weight, and a second metal selected from the group consisting of cobalt, ruthenium, zinc, molybdenum, manganese, titanium, tin, cadmium, boron, and iridium, in an amount of from about 0.05 to about 25% by weight of the supported catalyst.

20070172417, Jul 26, 2007

Dec 21, 2006

11/642895

Qinglin Zhang - Manalpan NJ, US
Ying Wu - Red Bank NJ, US
Gregory Smith - Marlboro NJ, US
Michael Binder - Brooklyn NY, US

B01J 21/02

423648100, 502325000, 502321000, 502324000, 502338000, 502350000, 502352000, 502300000, 502337000, 502202000

Supported catalysts and methods are provided to promote hydrogen generation from the hydrolysis of boron hydrides. The supported catalysts contain a supported metal comprising at least one transition metal selected from the group consisting of cobalt, ruthenium, zinc, molybdenum, manganese, titanium, tin, cadmium, and iridium, in an amount of from about 0.1 to about 20% by weight of the supported catalyst.

20070264190, Nov 15, 2007

May 9, 2006

11/430090

Qinglin Zhang - Manalpan NJ, US
Ying Wu - Red Bank NJ, US

C01B 3/02
B01J 8/02
H01M 8/06

423648100, 422211000, 429019000

Reactors with a dynamic compression elements that control the catalyst bed structure and hydrodynamic conditions inside the reactor in response to physical and structural changes in the catalyst bed, and methods of operating catalytic reactors are provided. The reactors are adjustable and/or can self-adjust in response to changes in the packing of the catalyst bed due, for example, to the attrition of the catalyst. The catalyst reactor designs improve operation of fixed bed reactors and enable the use of a variety of catalysts and supports, including materials that would not typically be considered for use in fixed bed reactors, such as those with limited durability or with moderate mechanical strength.

20080077019, Mar 27, 2008

Sep 21, 2007

11/903300

Song Xiao - Beijing, CN
Pei Cai - Beijing, CN
Jun Yang - Beijing, CN
Xiu Deng - Beijing, CN
Ying Wu - Cedar Grove NJ, US

A61B 6/00

600474000

A system, an apparatus and a method for human health evaluation utilizing the TMT mapping technology is disclosed. The method comprises scanning body areas of a patient utilizing an infrared camera, detecting abnormalities in the body of the patient, analyzing abnormalities of the patient against information stored in a database, and reporting results to the patient in a pre-determined format. The method provides an earlier discovery of disease by mapping and analyzing abnormal temperatures changes in the body, which can help prevent the disease from progressing at an early stage.